Early-stage evidence

Emerging Research

Experimental compounds attract a lot of attention in the healthy-aging space. This section keeps them clearly separated from our main reviews so it is always obvious which claims rest on completed clinical trials and which rest on animal studies, biomarkers or early human work.

Everything in this section is early-stage. Promising mechanistic or animal findings are not the same as proven clinical benefit in people, and none of these compounds has been shown to extend human lifespan. We list them so you can follow the research with clear expectations — not as recommendations.

NMN and nicotinamide riboside (NAD+ precursors)

Early human trials

Limited evidence

The claim: Marketed to restore declining NAD+ levels and slow cellular aging.

What looks promising: These compounds reliably raise blood NAD+ levels in humans and are well tolerated in trials up to about a year.
What is still missing: Raising NAD+ is a biomarker change, not a health outcome. Human trials have not shown consistent improvements in strength, cognition, insulin sensitivity or any aging endpoint.

Safety: Short-term safety looks good in published trials. Long-term safety in adults over 65 is not established.

Urolithin A

Small human trials, mixed results

Limited evidence

The claim: Promoted for mitophagy — clearing damaged mitochondria to improve muscle endurance.

What looks promising: Randomised trials in middle-aged and older adults report improvements in muscle endurance measures and mitochondrial gene expression.
What is still missing: Effects on strength and walking performance have been inconsistent, trials are small and several are industry-funded.

Safety: Well tolerated in trials to date; long-term data are limited.

Spermidine

Early human trials

Limited evidence

The claim: Autophagy induction, cognition and cardiovascular aging.

What looks promising: Strong animal lifespan data and observational human studies linking higher dietary spermidine to lower mortality.
What is still missing: The main randomised memory trial in older adults did not find a significant cognitive benefit. Observational diet links cannot establish cause.

Safety: Food-level intake is safe; supplement-level long-term safety is not characterised.

Senolytics (fisetin, quercetin combinations)

Animal and cell studies only

Limited evidence

The claim: Clearing senescent 'zombie' cells to reverse aspects of aging.

What looks promising: Striking results in mice, and a serious clinical trial programme is now underway in humans.
What is still missing: Human efficacy is essentially unestablished. Consumer doses, schedules and formulations are not the ones being tested clinically.

Safety: Quercetin interacts with several medications through CYP enzymes. Do not self-experiment with high-dose intermittent protocols without medical supervision.

Calcium alpha-ketoglutarate (Ca-AKG)

Animal and cell studies only

Limited evidence

The claim: Reducing biological age and extending healthspan.

What looks promising: Mouse studies showed compressed morbidity — more healthy time, not just more time.
What is still missing: Human evidence is limited to small uncontrolled studies using epigenetic-clock readouts, which are not validated health outcomes.

Safety: Few reported problems, but human data are too thin to characterise risk.

Collagen peptides for joints and skin

Small human trials, mixed results

Mixed evidence

The claim: Rebuilding cartilage and reversing skin aging.

What looks promising: Several randomised trials report modest improvements in skin elasticity and joint discomfort scores.
What is still missing: Many trials are small and manufacturer-funded, and improvements in symptom scores are not evidence of cartilage regrowth.

Safety: Generally well tolerated; it is simply hydrolysed protein.

How to read early-stage aging research

A change in a biomarker — NAD+ level, an epigenetic clock reading, a gene-expression score — is not a health outcome.
Mouse lifespan results have a poor track record of translating to people, and the doses used are often far higher than consumer products.
Ask who funded the trial, how many people were in it, how long it ran, and whether the primary outcome was pre-specified.
For adults over 65, interaction risk matters more than upside. Review anything experimental with your pharmacist before adding it to an existing medication list.

For compounds with completed clinical evidence, see our amino acids review and full supplement comparisons.